Amylyx Pharmaceuticals, Inc.
AMLX
$13.95
-$0.10-0.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.03% | 17.03% | -15.42% | 4.37% | 48.36% |
| Total Depreciation and Amortization | -10.00% | -14.89% | -9.62% | -2.50% | -27.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.06% | -4.24% | 18.73% | 0.96% | -87.76% |
| Change in Net Operating Assets | 104.75% | -119.42% | 208.26% | 65.54% | -151.99% |
| Cash from Operations | 8.12% | -20.28% | 36.60% | 32.51% | -41.95% |
| Capital Expenditure | -258.33% | -41.18% | -54.55% | 99.97% | -190,747.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 461.86% | -77.14% | 152.72% | -143.13% | 160.85% |
| Cash from Investing | 462.80% | -77.23% | 152.67% | -167.19% | 67.41% |
| Total Debt Issued | -100.20% | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -85.86% | 3,593.06% | -92.58% | 555.41% | -69.86% |
| Repurchase of Common Stock | 90.34% | -2,000.97% | 88.36% | -2,228.95% | 90.75% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.11% | 618,183.87% | -100.05% | 59,592.73% | 37.50% |
| Foreign Exchange rate Adjustments | -21.85% | -75.16% | 208.63% | 137.52% | -322.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.11% | 10,035.90% | 90.48% | -417.15% | 327.93% |